Objectives: To review the different interests and needs of industry and academic users of human biomaterials. Methods: A review of the current literature and interviews with involved parties. Questionnaires were e-mailed to assess current attitudes towards biobanking and opinions of trends and implications for the future. The organisations included commercial biobanks, charitable foundations, academic biobanks, and hospital sites. Results: Biobanks have the potential to have a critical impact across several industrial sectors, and their future success will depend on satisfying the differing needs of each group. There is a growing need for greater collaboration between researchers and biobanks, and if the involvement of industry is not sought by biobanks to create conditions that support the effective use of resources, there is a risk that samples will not be collected or used to the best advantage. Conclusions: It is evident that industry can play a vital role in the innovation process of biobanking, both in terms of the collecting and processing methods and the nature of the disease and sample types collected. With this feedback, biobanks can be utilised effectively to advance research to the benefits of all to the best advantage.

Keywords:
Biobank, Human biomaterials, Biospecimens
1.
Garnier JP: Rebuilding the R&D engine in big pharma. Harv Bus Rev 2008;86:68-70, 72-76, 128.
2.
GBI Research Release: Biobank boom damaged by lack of tissue samples. http://www.gbiresearch.com/pressreleasedetails.aspx?title=Pharmaceuticals_and_Healthcare&prid=76.
3.
Labant MA: Biobank diversity facilitates drug and diagnostic development. Genet Eng Biotech News 2012;32:42.
4.
Greaves P, Williams A, Eve M: First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov 2004;3:226-236.
5.
Ledford H: Translational research: 4 ways to fix the clinical trial. Nature 2011;477:526-528.
6.
Liu Y-T, Wang G-J, Liu C-X: Introducing FDA's white paper: challenge and opportunity on the critical path to new medical products. Asian J Pharmacodyn Pharmacokinet 2008;8:67-77.
7.
Mayeux R: Biomarkers: potential uses and limitations. NeuroRx 2004;1:182-188.
8.
Grizzle WE, Bell WC, Sexton KC: Issues in collecting, processing and storing human tissues and associated information to support biomedical research. Cancer Biomark 2010;9:531-549.
9.
Henderson GE, et al: Characterizing biobank organizations in the U.S.: results from a national survey. Genome Med 2013;5:3.
10.
Biobanking for Medicine: Technology and Market 2013-2023. London, Visiongain, 2013.
11.
Puchois P, Lisa B, Van Gool M, Van Gool A: The cardinal role of biobanks and human biospecimen collections in biomarker validation: issues impeding impact of biomarker research outcomes; in Horvatovich P, Bischoff R (eds): Comprehensive Biomarker Discovery and Validation for Clinical Application. RSC Drug Discovery Series. London, Royal Society of Chemistry, 2013, vol 33, pp 73-110.
12.
Steinsbekk K, Myskja B, Solberg B: Broad consent versus dynamic consent in biobank research: is passive participation an ethical problem? Eur J Hum Genet 2013;21:897-902.
13.
Cambon-Thomsen A, Rial-Sebbag E, Knoppers BM: Trends in ethical and legal frameworks for the use of human biobanks. Eur Respir J 2007;30:373-382.
15.
Laage-Hellman J: The industrial use of biobanks in Sweden: an overview; in Hansson MG (ed): The Use of Human Biobanks: Ethical, Social, Economical and Legal Aspects. Uppsala, Uppsala University, 2001, pp 15-34.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.